Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Total Liabilities: 2009-2024

Historic Total Liabilities for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $111.3 million.

  • Ligand Pharmaceuticals' Total Liabilities rose 363.20% to $526.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $526.6 million, marking a year-over-year increase of 363.20%. This contributed to the annual value of $111.3 million for FY2024, which is 29.00% up from last year.
  • As of FY2024, Ligand Pharmaceuticals' Total Liabilities stood at $111.3 million, which was up 29.00% from $86.3 million recorded in FY2023.
  • Ligand Pharmaceuticals' Total Liabilities' 5-year high stood at $652.8 million during FY2020, with a 5-year trough of $86.3 million in FY2023.
  • For the 3-year period, Ligand Pharmaceuticals' Total Liabilities averaged around $120.9 million, with its median value being $111.3 million (2024).
  • Its Total Liabilities has fluctuated over the past 5 years, first plummeted by 65.33% in 2022, then grew by 29.00% in 2024.
  • Yearly analysis of 5 years shows Ligand Pharmaceuticals' Total Liabilities stood at $652.8 million in 2020, then decreased by 27.01% to $476.4 million in 2021, then slumped by 65.33% to $165.2 million in 2022, then plummeted by 47.75% to $86.3 million in 2023, then grew by 29.00% to $111.3 million in 2024.